Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AGIO is in the long-term down -56% below S&P in 6 years.
Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-6||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||306.63%||Sales Growth - Q/Q||133.68%||P/E||-8.63|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-9.74%||ROE||-10.83%||ROI|
|Current Ratio||10.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-51.61%||Net Profit Margin||-50.7%||Dividend Payout Ratio|
|Cash From Financing Activities||1.82 M||Cash From Investing Activities||44.99 M||Cash From Operating Activities||-25.59 M||Gross Profit|
|Net Profit||-4.96 M||Operating Profit||-5.2 M||Total Assets||474.34 M||Total Current Assets||364.14 M|
|Total Current Liabilities||36.38 M||Total Debt||Total Liabilities||47.52 M||Total Revenue||34.2 M|
|High 52 week||75.11||Low 52 week||42.73||Last close||62.35||Last change||5.93%|
|RSI||68.62||Average true range||2.74||Beta||1.94||Volume||828.59 K|
|Simple moving average 20 days||13.04%||Simple moving average 50 days||18.89%||Simple moving average 200 days||3.15%|
|Performance Week||5.16%||Performance Month||20.07%||Performance Quart||-5.23%||Performance Half||4.56%|
|Performance Year||26.83%||Performance Year-to-date||35.22%||Volatility daily||2.87%||Volatility weekly||6.41%|
|Volatility monthly||13.13%||Volatility yearly||45.49%||Relative Volume||130.51%||Average Volume||563.62 K|
|New High||New Low|
2019-06-18 08:40:12 | Agios AGIO Catches Eye: Stock Jumps 5.4%
2019-06-18 08:06:00 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-17 09:59:49 | Volatility 101: Should Agios Pharmaceuticals NASDAQ:AGIO Shares Have Dropped 50%?
2019-06-14 18:28:21 | Is Agios Pharmaceuticals Inc AGIO Going to Burn These Hedge Funds?
2019-06-13 08:02:28 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-11 08:03:03 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-06 09:17:39 | Life sciences VC firm Third Rock raises $770M in its largest round ever
2019-06-04 08:04:31 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-06-03 08:00:00 | Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® ivosidenib in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia AML Not Eligible for Intensive Chemotherapy
2019-06-01 09:31:01 | Agios Pharmaceuticals AGIO Down 8% Since Last Earnings Report: Can It Rebound?
2019-06-01 08:02:30 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-05-16 10:49:02 | Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
2019-05-15 23:39:03 | Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight
2019-05-15 17:41:30 | Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more
2019-05-15 16:05:00 | Agios to Present Clinical Data from its IDH Program at ASCO
2019-05-14 11:22:45 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-05-07 08:04:53 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-05-04 01:17:15 | Edited Transcript of AGIO earnings conference call or presentation 2-May-19 12:00pm GMT
2019-05-03 10:19:02 | Agios AGIO Earnings and Revenues Surpass Estimates in Q1
2019-05-02 14:59:12 | Agios Pharmaceuticals Inc AGIO Q1 2019 Earnings Call Transcript
2019-05-02 13:18:47 | Agios Announces FDA Approval of Supplemental New Drug Application sNDA for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia AML Not Eligible for Intensive Chemotherapy
2019-05-02 10:15:02 | Agios Pharmaceuticals AGIO Reports Q1 Loss, Tops Revenue Estimates
2019-05-02 09:03:21 | Agios Pharmaceuticals: 1Q Earnings Snapshot
2019-05-02 07:00:00 | Agios Reports Business Highlights and First Quarter 2019 Financial Results
2019-05-02 06:00:00 | Agios Pharmaceuticals, Inc. to Host Earnings Call
2019-04-27 09:21:01 | Did Hedge Funds Drop The Ball On Agios Pharmaceuticals Inc AGIO?
2019-04-26 10:30:02 | Earnings Preview: Agios Pharmaceuticals AGIO Q1 Earnings Expected to Decline
2019-04-25 16:00:00 | Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019
2019-04-09 10:47:38 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-04-02 16:00:00 | Agios Announces New Commercial Leadership Structure
2019-04-02 10:09:02 | AVEO Reports Positive Results on Leukemia Drug, Shares Up
2019-03-27 10:48:02 | Agios AGIO Surges More Than 40% Year to Date: Here's Why
2019-03-27 10:45:02 | Agios Gains Breakthrough Therapy Status for Tibsovo Combo
2019-03-26 16:00:00 | Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® ivosidenib in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia AML with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
2019-03-26 08:57:08 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-03-16 09:30:01 | Why Is Agios Pharmaceuticals AGIO Up 13.2% Since Last Earnings Report?
2019-03-06 14:01:46 | All You Need To Know About Agios Pharmaceuticals, Inc.’s NASDAQ:AGIO Financial Health
2019-02-25 07:00:00 | Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia AML Patients
2019-02-22 07:25:00 | Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy — Research Highlights Growth, Revenue, and Consolidated Results
2019-02-21 09:34:02 | Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
2019-02-20 15:43:40 | Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT
2019-02-20 07:00:00 | Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® ivosidenib for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock